Immuneering Corp financial data

Symbol
IMRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
245 Main Street, Second Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.29K % -21.9%
Debt-to-equity 12.3 % +24.7%
Return On Equity -66 % -41.5%
Return On Assets -58.8 % -38.4%
Operating Margin -12.3M % -127560%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 239M USD +113%
Weighted Average Number of Shares Outstanding, Basic 29.7M shares +3.51%
Weighted Average Number of Shares Outstanding, Diluted 29.7M shares +3.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense 43.8M USD +12.7%
General and Administrative Expense 16.6M USD +1.02%
Operating Income (Loss) -60.5M USD -9.23%
Net Income (Loss) Attributable to Parent -56.1M USD -8.06%
Earnings Per Share, Basic -1.9 USD/shares +1.04%
Earnings Per Share, Diluted -1.9 USD/shares +1.04%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.7M USD -42.6%
Marketable Securities, Current 32.9M USD -55.7%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 63.7M USD -42.9%
Property, Plant and Equipment, Net 1.29M USD -5.54%
Operating Lease, Right-of-Use Asset 3.83M USD -8.73%
Goodwill 6.69M USD 0%
Other Assets, Noncurrent 1.23M USD +65.1%
Assets 77.1M USD -38.3%
Accounts Payable, Current 2.62M USD -2.63%
Accrued Liabilities, Current 3.76M USD +54.8%
Liabilities, Current 6.78M USD +23.8%
Operating Lease, Liability, Noncurrent 4M USD -7.22%
Other Liabilities, Noncurrent 9.9K USD
Liabilities 10.8M USD +10.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -192M USD -41.4%
Stockholders' Equity Attributable to Parent 66.3M USD -42.4%
Liabilities and Equity 77.1M USD -38.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.5M USD -7.44%
Net Cash Provided by (Used in) Financing Activities 980K USD +309%
Net Cash Provided by (Used in) Investing Activities 21.4M USD +12.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.88M USD +43.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.7M USD -42.6%
Deferred Tax Assets, Valuation Allowance 43.3M USD +35.1%
Deferred Tax Assets, Gross 43.7M USD +33%
Operating Lease, Liability 4.31M USD -7.16%
Depreciation 90.2K USD +17.9%
Payments to Acquire Property, Plant, and Equipment 37.5K USD +33.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.1M USD -8.43%
Lessee, Operating Lease, Liability, to be Paid 6.33M USD -11%
Property, Plant and Equipment, Gross 2.2M USD +13.6%
Operating Lease, Liability, Current 311K USD -6.38%
Lessee, Operating Lease, Liability, to be Paid, Year Two 762K USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 740K USD +0.98%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +11%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.02M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 785K USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 19.1M USD -8.38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 700K USD +29.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 808K USD +3%
Operating Lease, Payments 193K USD -11.1%
Additional Paid in Capital 258M USD +2.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 29.3K USD 0%
Depreciation, Depletion and Amortization 90.5K USD +15.7%
Deferred Tax Assets, Net of Valuation Allowance 390K USD -49.9%
Share-based Payment Arrangement, Expense 5.19M USD +10%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%